Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: even the “beat” of street expectation, doesn’t mean much in this sector

February 27, 2019 7:36am

Forecasts and earning that surpass are not being recognized

It’s grabbing and selling as one can; as much as there is success, the downside pessimism is always at the tip of the sell button

Quarterly results: Ionis Pharmaceuticals (IONS) and Intellia Therapeutics (NTLA)

Offering priced: Ultragenyx Pharmaceuticals (RARE) prices 5.072 M share offering at $60.00

Pre-open indications: 3 BUYs, 2 SELLs and 2 TRADEs

I answer one question, in which company should investors put, keep and commit their money!

RMi outlines preludes and aftermaths defining the daily dosage of facts and objectivity!

U.S. stock index futures are in the red and slipping

Dow futures are DOWN -0.23% (-60 points), S&P futures are DOWN -0.19% (-6 points) and NASDAQ futures are DOWN -0.18% (-13 points)

U.S. stock index futures were lower after Fed Chair Powell reiterated the central bank's shift to a more "patient" approach to monetary policy;

European stocks traded in the red as investors digested the latest political and economic news from around the world;

Asian shares in China closed mixed while stocks in Japan, South Korea and Australia gained on the day

Data docket: advanced economic indicators for December will be released at around 8:30 a.m. ET. Pending home sales for January and factory orders for December are both set to follow later in the session.

Wednesday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating

The SPDR S&P Biotech ETF (XBI) is NOT indicating

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating

The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.36% DOWNSIDE

Henry’omics:

Quarterly results could be holding the sector down as expectations and forecasts are being ignored … if strength is available, it is being sold into.

Patience is a virtue but, hardly a share holding variable!

From Tuesday’s closing bell post, “after an acquisition based surge … strength was sold into; there is the usual profit-taking of upside value.”

Range of the 20 upside was +0.07% (VYGR) to +7.29% (FIXX) while the 24 downside ranged from -0.03% (ONCE) to -8.70% (CRSP) with 1 flat close (BSTG).
9 out of the 20 upside had higher (than the 3 month average) volume
12 out of the 24 downside experienced greater volume (than the 3 month average);
In 18 sessions in February, there were 9 negative and 7 positive closes, 1 holiday and 1 vacation day

Last night, I also stated yesterday was “a busy day of 3 Q4 results, 2 offerings announced – 1 priced and a clinical initiative that got … SOLD into! What is my favorite analogy … the sector and Icarus flying so high and getting burned by the heights and the proximity to the sun?

Companies in my headlights – It’s your decision; I provide an idea and context:

AxoGen (AXGN) closed down -$0.16 to $17.89 after announcing an adjusted net loss for the fourth quarter of 2018 was $3.6 million, or $0.09 per share, compared with adjusted net loss of $1.4 million, or $0.04 per share, in Q4/17 – SELL;

Intellia therapeutics (NTLA) closed up +$0.15 to $14.51. The net loss was $19.1 million or -$0.43 per share for Q4/18, compared to $24 million or -$0.61 per share during Q4/17.Cash position ($314 M which included marketable securities) was supported by use of its ATM, collaboration revenue while R&D and G&A decreased – TRADE;

Ionis Pharmaceuticals (IONS) closed down -$0.05 to $61.82 and then reported net income of $320 million or +$2.32 as compared to $274 million or -$0.03 for; $2.1 billion goes a long for a runway. The increase in Ionis' cash, cash equivalents and short-term investments was primarily due to the $1 billion Ionis received from Biogen (BIIB) for the 2018 strategic neurology collaboration – BUY;

Sage Therapeutics (SAGE) closed down - $6.61 to $152.76. SAGE priced a 3.33 M share offering at $150.00 – BUY;

Ultragenyx Pharmaceuticals (RARE) closed down -$1.86 to $61.51 after news of a 5.02 M share offering priced at $60.00 that was not priced … https://www.regmedinvestors.com/articles/10731 – SELL;

Voyager Therapeutics (VYGR) closed up +$0.01 to $13.87 after Monday’s $13.86 and Friday’s +$2.44 to $13.12 and is up +$0.03 or +0.22% in the pre-market after announcing Q4 and FY18 results following an AbbVie (ABBV)exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases (synucleinopathies) characterized by the abnormal accumulation of misfolded alpha-synuclein protein - Maintaining BUY;

CRISPR Therapeutics (CRSP) closed down -$3.24 to $36.20 and has a negative -$0.20 or -0.55% aftermarket indication. January started out at $29.87 and February at $31.92 which as seen the share price jive and dive as a trading stock – TRADE;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.